SecBot SecBot
8-K ·Filed Feb 25, 2026

PTGX

Protagonist Therapeutics, Inc
MIXED
Impact 6/10
Horizonmonths Processed8mo ago SEC0001104659-26-019658
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

While the financials show a significant decline due to non-recurring 2024 milestones, traders should focus on the upcoming regulatory catalysts (rusfertide and ICOTYDE FDA decisions) and the potential for Protagonist to gain full U.S. rights and profits from rusfertide. The strong cash position reduces near-term dilution risk.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$88.39
T+0 close · Feb 25, 2026 · via day close
Latest settled
+12.22%
T+60 · $99.19
Vs SPY
+4.05%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $88.39entry
  2. T+1 · 9mo ago +4.17%α +4.65% · $92.08
  3. T+5 · 9mo ago +3.42%α +4.58% · $91.41
  4. T+20 · 8mo ago +15.59%α +22.00% · $102.17
  5. T+60 · 6mo ago +12.22%α +4.05% · $99.19
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Protagonist Therapeutics reported a significant year-over-year decline in revenue and a net loss for 2025, driven by the non-recurrence of large milestone payments from 2024. However, the company highlighted major upcoming catalysts including potential FDA approvals for rusfertide and ICOTYDE, a planned opt-out from profit sharing with Takeda, and a strong cash position extending into 2028.

Key Financial Metrics

Revenue
$46.0M
-89.4% YoY
EPS
$-2.05

Key Facts

  • License and collaboration revenue dropped to $46.0 million in 2025 from $434.4 million in 2024, primarily due to the absence of a $300 million upfront payment from Takeda and a $165 million milestone from J&J in 2024.
  • The company reported a net loss of $130.1 million for 2025, compared to net income of $275.2 million in 2024.
  • Cash, cash equivalents, and marketable securities were $646 million as of December 31, 2025, providing a cash runway into at least 2028.
  • The company submitted an NDA for rusfertide and expects a U.S. regulatory decision for ICOTYDE in 2026.
  • Protagonist expects to opt-out of the 50:50 profit and loss sharing arrangement with Takeda for rusfertide in Q2 2026.

Financial Impact

Revenue declined by $388.4 million year-over-year. Net income swung to a $130.1 million loss from a $275.2 million gain.

revenuenet incomeeps

Risk Factors

  • Failure to gain FDA approval for rusfertide or ICOTYDE.
  • The significant revenue decline highlights the company's dependence on large, non-recurring milestone payments.
  • Increased R&D expenses could pressure the cash runway if clinical programs face delays or setbacks.

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-019658
Document: tm267184d1_8k.htm0001104659-26-019658
Document: 0001104659-26-019658-index-headers.html0001104659-26-019658
Document: 0001104659-26-019658-index.html0001104659-26-019658
Document: 0001104659-26-019658.txt0001104659-26-019658

Track record

11 reports on PTGX

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +31.42% at T+60 after the May 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 5, 202611d ago 8-K Bullish 7/10 Entry $132.04 Now $124.83 −5.46% settles Feb 4
  2. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
  3. Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
  4. Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
  5. Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
  6. Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
  7. May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
  8. May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
  9. May 8, 202627w ago Insider Cluster Neutral 5/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
  10. May 5, 202627w ago 8-K Bullish 7/10 Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 19m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026